OakChart

Billiontoone Inc

BLLNHealthcare·Diagnostics & Research·USA·Mid·NASD·Nov 11 • 10:37 AM ET

111.13-0.87 (-0.78%)
2026-11-11 16:37 CET
Market cap
5,350.79 USD m
Revenue, TTM
436.87 USD m
Net income, TTM
47.83 USD m
Free cash flow, TTM
33.90 USD m
EPS diluted, TTM
0.91
P/E
122.55
Compare

Price

BLLN against its 20, 50 and 200-day averages
2050200beatmiss
80.00100.00120.00140.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BLLNclose 111.1320-day 109.5250-day 106.60200-day 97.42111.1352w high

26.1% under the 52-week high of 150.44 on 5 Aug 2026. 52-week low 61.96 on 12 Mar 2026. Last 15 sessions, 19.0% high to low

Profile

BLLN
52-week range, 56% of the way up
61.96150.44

BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. Its patented Quantitative Counting Templates (QCT) molecular counting platform is a multiplex technology capable of accurately counting DNA molecules at the single-molecule level. The was founded by Oguzhan Atay, Sukrit Silas, and David Tsao in 2016 and is headquartered in Menlo Park, CA.

Employees713
IPONov 06, 2025
Beta-0.20
ATR, 14d6.42
Rel volume0.88
Short float12.21%
Insider own49.09%
Inst own30.03%

Snapshot

6 groups

Valuation

Index-
Market Cap5.31B
Enterprise Value4.89B
Income47.83M
Sales436.87M
Book/sh11.89
Cash/sh11.75
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees713
IPONov 06, 2025

Ratios

P/E122.55
Forward P/E115.59
PEG0.91
P/S12.15
P/B9.34
P/C9.46
P/FCF156.61
EV/EBITDA84.83
EV/Sales11.19
Quick Ratio10.89
Current Ratio11.25
Debt/Eq0.25
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)0.91
EPS next Y0.96
EPS next Q0.15
EPS this Y574.49%
EPS next Y1.82%
EPS next 5Y127.03%
EPS past 3/5Y- -
Sales past 3/5Y106.24% -
EPS Y/Y TTM423.21%
Sales Y/Y TTM71.90%
EPS Q/Q883.89%
Sales Q/Q47.24%
EarningsNov 04 AMC
EPS/Sales Surpr.119.18% 6.20%

Ownership

Insider Own49.09%
Insider Trans-2.17%
Inst Own30.03%
Inst Trans-15.19%
ROA8.79%
ROE12.82%
ROIC6.83%
Gross Margin71.41%
Oper. Margin10.23%
Profit Margin10.95%
SMA201.47%
SMA504.25%
SMA20014.08%
Trades-

Technical

Shs Outstand43.13M
Shs Float24.32M
Short Float12.21%
Short Ratio4.92
Short Interest2.97M
52W High150.44 -26.13%
52W Low61.96 79.36%
Volatility7.13% 5.73%
ATR (14)6.42
RSI (14)53.18
Beta-0.20
Rel Volume0.88
Avg Volume603.14K
Volume113,664

Performance

Perf Week-2.42%
Perf Month17.67%
Perf Quarter18.17%
Perf Half Y22.67%
Perf YTD35.79%
Perf Year7.10%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.25
Target Price129.00
Prev Close112.00
Price111.13
Change %-0.78%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Sep 02, 2026InitiatedCCanaccord GenuityBuy$120+8.0%
Jan 06, 2026InitiatedGGuggenheimBuy$120+8.0%
Dec 01, 2025InitiatedWWilliam BlairOutperform
Dec 01, 2025InitiatedWWells FargoEqual Weight$110-1.0%
Dec 01, 2025InitiatedSStifelBuy$145+30.5%
Dec 01, 2025InitiatedPPiper SandlerOverweight$150+35.0%
Dec 01, 2025InitiatedJJP MorganOverweight$150+35.0%
Dec 01, 2025InitiatedJJefferiesHold$117+5.3%
Dec 01, 2025InitiatedBBTIG ResearchBuy$160+44.0%

Peers

Mkt cap
TickerCompanyMkt cap
NTRANatera Inc46.48B
GHGuardant Health Inc21.50B
MYGNMyriad Genetics Inc558.05M
LHLabcorp Holdings Inc30.16B
WGSGeneDx Holdings Corp1.77B
DGXQuest Diagnostics Inc28.50B
CDNACaredx Inc4.30B
GRALGRAIL Inc5.74B
NEONeogenomics Inc2.22B
FLGTFulgent Genetics Inc741.91M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ten Bosch John RoderickSVP of Laboratory OperationsNov 02 '26Sale113.172,834320,72416,551Nov 04 08:42 PM
Atay OguzhanChairman and CEONov 02 '26Option Exercise2.8025,00170,00325,001Nov 04 08:42 PM
Atay OguzhanChairman and CEONov 02 '26Sale109.2425,0012,730,9940Nov 04 08:42 PM
Atay OguzhanChairman and CEONov 02 '26Sale113.175,334603,649141,167Nov 04 08:42 PM
Tsao DavidChief Technology OfficerNov 02 '26Option Exercise2.8020,00056,00021,000Nov 04 08:42 PM
Tsao DavidChief Technology OfficerNov 02 '26Sale109.2420,0002,184,8541,000Nov 04 08:42 PM
ten Bosch John RoderickOfficerNov 02 '26Proposed Sale113.172,834320,724Nov 02 02:25 PM
Atay OguzhanMember of immediate family ofNov 02 '26Proposed Sale113.175,334603,649Nov 02 01:08 PM
Atay OguzhanOfficerNov 02 '26Proposed Sale113.1725,0012,829,363Nov 02 12:53 PM
Tsao DavidOfficerNov 02 '26Proposed Sale113.321,750198,310Nov 02 10:10 AM
Tsao DavidOfficerNov 02 '26Proposed Sale113.3220,0002,266,400Nov 02 09:59 AM
Atay OguzhanChairman and CEOOct 28 '26Option Exercise2.808,33323,3328,333Oct 30 06:54 PM
Atay OguzhanChairman and CEOOct 28 '26Sale118.008,333983,2940Oct 30 06:54 PM
Atay OguzhanChairman and CEOOct 28 '26Sale118.002,667314,706146,501Oct 30 06:54 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
LFSCF/m Emerald Life Sciences Innovation ETFAUM: 130.02M
IHFiShares U.S. Healthcare Providers ETFAUM: 1.56B
XHSState Street SPDR S&P Health Care Services ETFAUM: 246.09M
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 130
  • BillionToOne Doubles The EPS Consensus And Raises Guidance Again, But A $7.6 Million True-Up And Slowing Growth Complicate The Beat (Earnings Whispers)
  • BillionToOne: Q3 Earnings Snapshot (Associated Press)
  • BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance (GlobeNewswire)
  • Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIG (Investing.com)
  • BillionToOne Must Show Its Second-Quarter Stall Was Payer Timing, Not Peak Growth (Earnings Whispers)
  • Loading…
  • BillionToOne to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
  • 7 healthcare stocks that stand out as investors pay up for the sector (MarketWatch)
  • BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
  • BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds (GlobeNewswire)
  • BillionToOne Stock Jumped 12% Yesterday. Heres What the Streets Target. (TIKR)
  • BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference (PR Newswire)
  • BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin (PR Newswire)
  • Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions (PR Newswire) -6.30%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.3200.1460.320122.98115.87
2026Q22026-08-050.1500.1830.148109.4109.227
2026Q12026-05-060.3400.0310.339108.497.147
2025Q42026-03-040.1100.0600.09696.0587.198
2025Q32025-12-090.1000.1400.03383.5082.904
2025Q22025-09-03-0.009--0.00666.71--
2026Q4--0.150--122.437
2027Q1--0.208--130.865
2027Q2--0.194--139.035
2027Q3--0.242--148.85
2027Q4--0.238--155.755
2028Q1--0.370--166.382
2028Q2--0.310--179.192
2028Q3--0.410--191.712
2028Q4--0.435--201.692

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY0.1400.1080.140305.11296.23
2026FY-0.944--457.69
2027FY-0.961--577.9
2028FY-1.638--725.57
2029FY-2.723--889.73
2030FY-2.895--1,041

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09841122.43120.07125.19
2026Q4S2026-11-06832122.28119.1125.19
2026Q4S2026-11-05822121.58116.9125.19
2026Q4S2026-11-04801121.12116.9126.03
2026Q4S2026-10-21801121.12116.9126.03
2026Q4S2026-10-20802121.12116.9126.03
2026Q4S2026-10-16812121.12116.9126.03
2026Q4S2026-10-13812121.12116.9126.03
2026Q4S2026-09-30812121.11116.9126
2026Q4S2026-09-28821121.32116.9126
2026Q4S2026-09-07921121.67116.9126
2026Q4S2026-09-01921121.66116.9126
2026Q4S2026-08-31921121.67116.9126
2026Q4S2026-08-24821121.86116.9126

Estimate history

EPS, annual-1.849-0.930.0640.9068
Period202320242025TTM
EPS, quarterly-0.333-0.257-0.089-0.0060.0330.0960.3390.1480.324
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual71.729152.582305.112436.87
Period202320242025TTM
Sales, quarterly38.41945.07758.96366.57383.52396.053108.388109.448122.981
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.7244.7245.80547.631
Period202320242025MRQ
Shares, quarterly44.7244.7244.7244.7245.76945.80545.98146.82747.631
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue436.87305.11152.5871.73
Cost of Goods Sold Incl. D&A124.9296.6571.6754.42
Gross Profit311.95208.4680.9217.31
Selling, General and Administrative Excl. Other267.26192.44128.0686.80
Research and Development66.4749.3836.6022.41
Other Operating Expense0.000.000.000.00
Operating Income44.6916.02-47.15-69.50
Interest Expense0.030.102.393.27
Unusual Expense7.228.51-2.3513.36
Net Income Before Taxes49.727.76-41.54-82.67
Income Taxes0.320.300.030.01
Consolidated Net Income47.832.92-41.57-82.68
Net Income From Continuing Operations47.832.92-41.57-82.68
Net Income47.832.92-41.57-82.68
EPS (Recurring)0.980.19-0.97-1.64
EPS (Basic, Before Extraordinaries)1.030.06-0.93-1.85
EPS (Diluted)0.910.06-0.93-1.85
EBITDA57.6227.93-35.46-63.03
Non-Operating Income (Expense)12.270.345.643.45
Other After Tax Adjustments-1.56-4.540.000.00
Stock Option Compensation Expense24.3012.576.613.83
Price To Earnings Ratio123.51123.51--
Price To Sales Ratio13.0912.29--
Gross Margin71.4168.3253.0324.13
Operating Margin10.235.25-30.90-96.89
Net Margin10.950.96-27.24-115.27
Shares Outstanding47.6345.8044.7244.72
Market Capitalization5,350.795,350.793,894.47-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue122.98109.45108.3996.0583.5266.5758.9645.08
Cost of Goods Sold Incl. D&A35.8432.3429.2927.4525.1123.1120.9919.36
Gross Profit87.1477.1179.1068.6058.4243.4737.9725.72
Selling, General and Administrative Excl. Other76.1271.6061.2658.2748.7845.0940.2937.41
Research and Development20.2217.3214.6914.2512.9511.7510.4311.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income11.025.5017.8310.339.63-1.63-2.31-11.69
Interest Expense0.010.010.010.000.020.030.040.05
Unusual Expense-1.482.974.261.473.940.013.090.85
Net Income Before Taxes17.397.5218.516.305.58-0.23-3.89-11.45
Income Taxes0.00-0.540.540.32-0.130.010.100.02
Consolidated Net Income17.398.0517.974.421.51-0.25-3.99-11.48
Net Income From Continuing Operations17.398.0517.974.421.51-0.25-3.99-11.48
Net Income17.398.0517.974.421.51-0.25-3.99-11.48
EPS (Recurring)0.300.190.400.120.09-0.01-0.04-0.24
EPS (Basic, Before Extraordinaries)0.370.170.390.100.03-0.01-0.09-0.26
EPS (Diluted)0.320.150.340.100.03-0.01-0.09-0.26
EBITDA14.618.9020.8213.2912.590.12-0.52-9.89
Non-Operating Income (Expense)4.894.994.95-2.56-0.101.441.561.14
Other After Tax Adjustments0.000.000.00-1.56-4.200.000.000.00
Stock Option Compensation Expense7.676.495.145.003.54---
Price To Earnings Ratio123.51259.30------
Price To Sales Ratio13.0916.4411.8112.29----
Gross Margin70.8670.4572.9771.4269.9465.2964.4057.06
Operating Margin8.965.0316.4510.7611.53-2.44-3.93-25.94
Net Margin14.147.3616.584.601.80-0.37-6.76-25.46
Shares Outstanding47.6346.8345.9845.8045.7744.7244.7244.72
Market Capitalization5,350.795,518.543,628.543,745.723,894.47---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments495.98191.4897.27
Short Term Receivables41.6224.719.09
Inventories17.558.737.20
Other Current Assets5.422.901.94
Total Current Assets560.56227.82115.50
Net Property, Plant & Equipment67.1068.8573.87
Total Investments and Advances0.000.000.00
Other Assets4.995.392.31
Total Assets632.65302.06191.68
Short Term Debt Incl. Current Port. of LT Debt5.606.2253.74
Accounts Payable7.184.303.21
Other Current Liabilities35.1817.869.85
Total Current Liabilities47.9628.3966.80
Long Term Debt103.30103.1692.60
Provision for Risks Charges0.000.000.00
Other Liabilities1.292.761.80
Total Liabilities152.55134.31161.20
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.00419.41249.53
Common Equity480.11-251.66-219.05
Total Shareholders Equity480.11167.7530.47
Accumulated Minority Interest0.000.000.00
Total Equity480.11167.7530.47
Total Liabilities & Stockholders Equity632.65302.06191.68
Book Value Per Share10.48-5.63-4.90
Tangible Book Value Per Share10.48-5.63-4.90
Full-Time Employees713--
Price to Book Ratio9.42-16.26-
Return on Assets0.62-16.84-
Return on Equity0.90-41.94-
Return on Invested Capital0.50-15.34-67.18
Quick Ratio11.327.721.62
Current Ratio11.698.031.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income49.397.45-41.57-82.68
Depreciation12.9311.9111.696.46
Other Funds (Non Cash)37.7527.295.2718.75
Funds from Operations100.0746.65-24.61-57.47
Extraordinary Item0.000.000.000.00
Changes in Working Capital-52.16-22.05-16.773.79
Cash from Operating Activities47.9124.59-41.38-53.67
Capital Expenditures-14.04-8.92-5.40-6.17
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments0.000.000.0090.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments0.000.000.0090.00
Other Uses0.000.00-0.03-0.99
Other Sources0.000.000.000.00
Cash from Investing Activities-14.04-8.92-5.4382.84
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock303.62290.55130.530.44
Repurchase of Common Pref Stock0.000.00-0.550.00
Sale of Common Pref Stock303.62290.55131.080.44
Proceedsfrom Stock Options289.44287.43131.080.39
Issuance or Reduction of Debt, Net29.32-1.7310.4812.96
Change in Long Term Debt29.32-1.7310.4812.96
Issuance of Long Term Debt30.050.0549.5515.05
Reduction of Long Term Debt-0.73-1.78-39.06-2.09
Net Financing Active Other Cash Flow-0.430.000.000.00
Other Financing Activities Uses-0.430.000.000.00
Cash from Financing Activities332.50288.82141.0213.40
Net Change in Cash366.36304.5094.2142.57
Free Cash Flow33.9015.71-46.78-59.85
Preferred Dividends (Cash Flow)-0.000.000.00
Price to Free Cash Flow168.70238.56--
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments561.51548.63537.45495.98195.15188.96
Short Term Receivables88.2874.8961.3041.6234.6530.44
Inventories21.8921.1419.2217.5517.3913.73
Other Current Assets10.416.726.175.424.533.02
Total Current Assets682.09651.38624.14560.56251.72236.15
Net Property, Plant & Equipment73.0872.7671.6767.1066.6968.39
Total Investments and Advances0.000.000.000.000.000.00
Other Assets5.315.564.924.999.118.09
Total Assets760.49729.70700.73632.65327.52312.63
Short Term Debt Incl. Current Port. of LT Debt7.176.766.245.605.655.84
Accounts Payable10.2312.218.707.187.817.95
Other Current Liabilities43.2436.7642.2235.1827.3326.08
Total Current Liabilities60.6455.7357.1647.9640.7839.87
Long Term Debt133.28137.16137.94103.30102.49100.88
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.030.000.001.294.352.72
Total Liabilities193.94192.89195.11152.55147.62143.48
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00419.41419.41
Common Equity566.55536.81505.62480.11-239.51-250.25
Total Shareholders Equity566.55536.81505.62480.11179.90169.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity566.55536.81505.62480.11179.90169.16
Total Liabilities & Stockholders Equity760.49729.70700.73632.65327.52312.63
Book Value Per Share11.8911.4611.0010.48-5.23-5.60
Tangible Book Value Per Share11.8911.4611.0010.48-5.23-5.60
Full-Time Employees---713-620
Price to Book Ratio9.4210.917.53-15.64-16.26-
Return on Assets8.796.13-0.36--
Return on Equity12.829.05-0.52--
Return on Invested Capital2.491.202.790.760.53-0.09
Quick Ratio10.8911.3110.5811.325.755.58
Current Ratio11.2511.6910.9211.696.175.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income17.398.0517.975.985.71-
Depreciation3.593.402.992.962.95-
Other Funds (Non Cash)6.609.548.9912.619.02-
Funds from Operations27.5821.0029.9521.5517.68-
Extraordinary Item0.000.000.000.000.00-
Changes in Working Capital-15.03-11.86-14.52-10.75-7.69-
Cash from Operating Activities12.559.1415.4310.7910.00-
Capital Expenditures-3.95-4.05-4.47-1.58-2.12-
Net Assets From Acquisitions0.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.00-
Purchase of Investments0.000.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.00-
Other Uses0.000.000.000.000.00-
Other Sources0.000.000.000.000.00-
Cash from Investing Activities-3.95-4.05-4.47-1.58-2.12-
Cash Dividends Paid0.000.000.000.000.00-
Preferred Dividends (Cash Flow)0.000.000.000.000.00-
Change in Capital Stock4.826.190.71291.89-1.24-
Repurchase of Common Pref Stock0.000.000.000.000.00-
Sale of Common Pref Stock4.826.190.71291.89-1.24-
Proceedsfrom Stock Options-7.246.150.58289.95-1.89-
Issuance or Reduction of Debt, Net-0.11-0.1029.80-0.28-0.44-
Change in Long Term Debt-0.11-0.1029.80-0.28-0.44-
Issuance of Long Term Debt0.000.0030.000.050.00-
Reduction of Long Term Debt-0.11-0.10-0.20-0.33-0.44-
Net Financing Active Other Cash Flow-0.430.000.000.000.00-
Other Financing Activities Uses-0.430.000.000.000.00-
Cash from Financing Activities4.286.0930.52291.61-1.68-
Net Change in Cash12.8811.1841.48300.826.19-
Free Cash Flow8.605.0910.969.267.87-
Price to Free Cash Flow168.70196.95----

Revenue breakdown

Clinical Trial Support and Other Services2024: 3.74M 2025: 3.05M
Oncology2024: 2.94M 2025: 24.95M
Prenatal2024: 145.90M 2025: 277.11M
United States2024: 152.58M 2025: 305.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.21%3.0M24.3M652.35K
2026-10-1512.23%2.9M24.0M673.65K
2026-09-3011.76%2.8M24.0M697.75K
2026-09-1510.95%2.6M24.0M712.19K
2026-08-319.81%2.3M24.0M758.75K
2026-08-148.50%1.9M22.9M774.40K
2026-07-318.34%1.9M23.0M748.41K
2026-07-1510.77%2.4M22.4M719.39K
2026-06-3010.85%2.4M22.3M673.27K
2026-06-158.09%1.8M22.3M575.98K
2026-05-2910.17%1.7M16.5M505.29K
2026-05-158.86%1.5M16.5M463.07K
2026-04-3011.66%2.3M19.7M329.70K
2026-04-159.37%1.9M20.7M303.52K
2026-03-317.93%1.6M20.7M272.85K
2026-03-136.33%1.3M20.7M266.76K
2026-02-275.67%1.2M20.6M227.65K
2026-02-134.80%1.0M20.6M210.08K
2026-01-304.41%0.9M20.9M240.83K
2026-01-153.40%0.7M20.9M240.39K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call55.0055.0059.000.003.9470.000.000.987-0.0780.006
call60.0049.8054.000.003.4710.000.000.985-0.0770.007
call65.0044.8049.200.003.1090.000.000.983-0.0760.007
call70.0039.9044.100.002.8050.000.000.981-0.0750.008
call75.0035.0039.200.002.3650.000.000.920-0.2940.026
call80.0030.2034.500.002.2120.000.000.909-0.2830.029
call85.0025.5029.700.002.0420.000.000.860-0.3990.039
call90.0020.7024.9015.401.75211.000.000.826-0.4200.045
call95.0015.9020.2018.301.56512.000.000.794-0.3960.050
call10011.8015.9016.101.39542.000.000.733-0.4180.058
call1058.1012.206.001.2741400.000.656-0.4300.064
call1105.508.506.501.1351480.000.560-0.4110.069
call1152.106.107.301.1053490.000.453-0.4080.069
call1201.704.502.321.1233330.000.365-0.4080.066
call1250.003.802.501.2501400.000.323-0.4400.063
call1300.003.303.431.2901080.000.264-0.4130.058
call1350.002.904.101.3581060.000.224-0.3970.053
call1400.002.853.401.45811.000.000.198-0.3960.049
call1450.002.601.041.5151180.000.181-0.3760.048
call1500.002.452.201.6061.000.000.165-0.3750.046
call1550.002.351.231.80714.000.000.156-0.4210.042
call1600.002.300.001.9080.000.000.148-0.4270.041
call1650.002.250.002.0020.000.000.140-0.4330.039
call1700.002.202.002.0901.000.000.133-0.4360.038
call1750.002.150.002.0870.000.000.129-0.4130.039
put55.000.002.150.002.8410.000.00-0.036-0.2170.014
put60.000.002.200.002.5360.000.00-0.040-0.2120.015
put65.000.002.250.352.25514.000.00-0.045-0.2070.017
put70.000.000.200.552.09227.000.00-0.058-0.2350.020
put75.000.002.350.311.74847.000.00-0.058-0.1950.020
put80.000.101.450.401.7598910.00-0.090-0.2750.029
put85.000.102.600.951.7991130.00-0.142-0.3860.039
put90.000.003.101.871.7151270.00-0.173-0.4230.045
put95.000.003.201.351.44595.000.00-0.200-0.3910.050
put1000.104.101.851.3634670.00-0.273-0.4340.058
put1051.105.203.301.2154550.00-0.347-0.4330.065
put1103.306.405.831.0334550.00-0.432-0.3980.069
put1156.008.8010.350.98730.000.00-0.538-0.3940.070
put1208.5012.300.000.9900.000.00-0.636-0.3930.066
put12512.5016.6020.901.0299.000.00-0.694-0.4040.061
put13016.6020.9022.561.1106.000.00-0.740-0.4040.057
put13521.3025.700.001.2020.000.00-0.775-0.3970.053
put14026.0030.5020.631.2964.000.00-0.793-0.4170.050
put14531.0035.3024.091.3993.000.00-0.814-0.4100.047
put15036.0040.100.001.4920.000.00-0.830-0.4090.044
put15541.0045.100.001.6340.000.00-0.842-0.4120.042
put16046.0050.000.001.7700.000.00-0.851-0.4180.041
put16551.0055.000.001.8450.000.00-0.858-0.4230.039
put17056.0060.000.001.9430.000.00-0.865-0.4260.038
put17561.0065.000.002.0370.000.00-0.871-0.4280.037

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-09SCHEDULE 13D/ASEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-303Initial statement of beneficial ownership of securities2026-09-30SEC
2026-10-28144Filing for proposed sale of securities under Rule 144.SEC
2026-10-28144Filing for proposed sale of securities under Rule 144.SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11005.84M4
2026-10006.67M9
2026-090013.08M11
2026-080010.70M7
2026-070012.82M9
2026-06009.36M9
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ADAMS STREET PARTNERS LLC3.72%
BAILLIE GIFFORD & CO2.29%
PRICE T ROWE ASSOCIATES INC /MD/2.20%
VANGUARD PORTFOLIO MANAGEMENT LLC1.83%
Invesco Ltd.1.82%
VANGUARD CAPITAL MANAGEMENT LLC1.74%
Neuberger Berman Group LLC1.66%
BAMCO INC /NY/1.61%
WASATCH ADVISORS LP1.07%
MILLENNIUM MANAGEMENT LLC0.92%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.57%
VANGUARD SMALL-CAP INDEX FUND1.14%
Invesco Discovery Fund1.13%
BARON DISCOVERY FUND0.62%
FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH0.60%
Oberweis Small-Cap Opportunities Fund0.57%
ADAMS STREET PRIVATE EQUITY NAVIGATOR FUND LLC0.54%
VANGUARD SMALL-CAP VALUE INDEX FUND0.36%
Wasatch Small Cap Growth Fund0.35%
LORD ABBETT DEVELOPING GROWTH FUND INC0.33%

OakChart. BLLN. Cached 15 minutes.